Conivaptan

Conivaptan
Systematic (IUPAC) name
N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
Identifiers
CAS number	210101-16-9
ATC code	?
PubChem	151171
Chemical data
Formula	C32H26N4O2
Mol. mass	498.583
Pharmacokinetic data
Bioavailability	N/A
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	Additional recommended knowledge Recognize and detect the effects of electrostatic charges on your balance Better weighing performance in 6 easy steps How to quickly check pipettes? ?
Legal status
Routes	iv

Conivaptan (vaprisol®, YM 087) is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.

Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

See also

• Tolvaptan